Non-Invasive Chromosomal Evaluation of 22q11.2

Overview

This study is being conducted to develop and evaluate a cell-free fetal DNA test (Harmony) for non-invasive prenatal detection of 22q11.2 chromosomal deletion or duplication.

Full Title of Study: “Non-Invasive Chromosomal Evaluation of 22q11.2 Using Cell-free Fetal DNA From Maternal Plasma”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 17, 2020

Arms, Groups and Cohorts

  • Confirmed 22q.11.2 deletion/duplication
  • Suspected 22q.11.2 deletion/duplication

Clinical Trial Outcome Measures

Primary Measures

  • Performance of Ariosa 22q.11.2 deletion/duplication assay in prenatal patients
    • Time Frame: 18 months

Participating in This Clinical Trial

Inclusion Criteria

1. Patient is ≥18 years of age and able to provide consent or, if under the age of 18, the patient has parental consent and child assent provided as required by the governing ethics committee. 2. If pregnant, patients must have a singleton pregnancy and be at least 10 weeks gestation at the time of the study blood draw. 3. Patients must meet at least one of the following conditions at the time of enrollment: 1. are pregnant with abnormal fetal cardiac findings on ultrasound and is undergoing evaluation with prenatal genetic testing or planned post-natal genetic testing in the immediate newborn period; 2. are pregnant with fetal ultrasound findings consistent with a 22q11.2 deletion/duplication phenotype and is undergoing evaluation with prenatal genetic testing or planned post-natal genetic testing in the immediate newborn period; 3. are pregnant with a fetus known to have a 22q11.2 deletion/duplication confirmed by genetic testing with documentation is available; 4. are biologically related parent of an enrolled child has chromosomal deletion/duplication in the region of 22q11.2; 4. If the site is selected to enroll control patients, they must be pregnant women undergoing prenatal genetic evaluation for 22q11.2 deletion/duplication. Exclusion Criteria Patients meeting any of the following criteria will be excluded from the study: 1. Patient has history of malignancy treated with chemotherapy and/or major surgery, or bone marrow transplant.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Cindy Cisneros
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Cindy Cisneros, CRA – Roche Sequencing Solutions
  • Overall Official(s)
    • Frank Ong, MD, Study Director, Roche Sequencing Solutions

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.